BRM:FRA
Bristol-Myers Squibb Co
€51,50
arrow_upward
+0,98%(+0,50) 1D
13 ຕ.ລ., 8 ໂມງ 29 ນາທີ 35 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BRM...
Open
€51,50
High
€51,50
Low
€51,50
Mkt. cap
117,62 ຕື້
Avg. vol.
186,00
Volume
0,00
52-wk high
€60,64
52-wk low
€36,65
No. of employees
32 ພັນ
Open
€51,50
High
€51,50
Low
€51,50
Mkt. cap
117,62 ຕື້
Avg. vol.
186,00
Volume
0,00
52-wk high
€60,64
52-wk low
€36,65
No. of employees
32 ພັນ
News stories
From web sources and news partners
ad-hoc-news.de
·
1 ຊົ່ວໂມງກ່ອນ
Bristol Myers Squibb reports positive ACTION-1 results: stock pre-market at EUR 51.72
Stocktwits
·
2 ຊົ່ວໂມງກ່ອນ
BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses
MarketWatch
·
11 ຊົ່ວໂມງກ່ອນ
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
Investor's Business Daily
·
11 ຊົ່ວໂມງກ່ອນ
Bristol Reverses Despite Double Win. But Its Key Rival Crashed.
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32,5 ພັນ
Founded1887
Headquartersນິວຢອກ, ລັດນີວຢອກ, ສະຫະລັດ
SectorPharmaceutical industry
Websitebms.com